Aneuploidy 5/9/15 by FISH

Alphabetical Test listing

Aneuploidy 5/9/15 by FISH-4280H (blood) or 4280G (bone marrow)

Aneuploidy 5/9/15 by FISH
4280H (blood) or 4280G (bone marrow)
Myeloma FISH panel
Plasma Cell Myeloma
Trisomy 5
Trisomy 9
Trisomy 15

Aneusomy of chromosomes 5, 9 and 15 are recurring abnormalities in plasma cell dyscrasia disorders including Plasma Cell Myeloma.

This test can be ordered individually or as part of a Plasma Cell Dyscrasia FISH Panel (See the individual panel test for more details).

Sodium heparin (Na hep) whole blood
5 mL
2.0 mL
  • Only one specimen tube is required to perform all ordered cytogenetics testing.
  • The more testing requested, the closer to the optimal volume requirements is required.
  • Immediately following collection, mix sample by inverting 8 - 10 times to prevent clotting.

Dk green Sodium heparin (Na hep), no gel

Bone marrow
EDTA whole blood (a chromosome analysis study is not recommended for this specimen type)

EDTA whole blood: (not recommeneded)

Lavender (EDTA), 4mL

Bone marrow: 10 mL (minimum 5 mL)

Bone marrow

Collect bone marrow aspirate in a sterile Sodium heparin (Na hep) syringe and transfer to a sterile vial/tube


- or -

Collect bone marrow in sterile syringe (non-heparinized) and transfer to a Dk green Sodium heparin (Na hep), no gel


EDTA whole blood:

Lavender (EDTA), 4mL

Bone marrow:

Sterile vial/tube

Dk green Sodium heparin (Na hep), no gel

  • AHL Cytogenetics oncology request


Pellets - 2 years
  • Improper label (unlabeled or mislabeled)
  • Wrong container (anticoagulant or solution)
  • Improper blood/anticoagulant ratio
  • Delay in transport
  • Improper storage
  • Leaking container
AHL - Cytogenetics: X
2 - 3 times per week
5 - 7 days

Fluorescence in situ hybridization (FISH)


Normal or Abnormal with interpretation.

Gain (trisomy) of either chromosome 5, 9 or 15 or in combination with each other is an indication of hyperdiploidy, an early indicator of a plasma cell disorder. A trisomy finding is considered a standard cytogenetics risk category in myeloma according to mSMART 3.0. This finding when found with one high risk cytogenetics abnormality (gain of 1q, IGH rearrangements with partner genes other than CCND1, or TP53 deletion) may ameliorate the risk stratification.

88271 x 3